
Novartis narrowed its mid-term sales growth outlook to 5% annually through 2031 at its London investor day, as patent expirations weigh on the Swiss drugmaker.
To read the March cover story in the PharmExec digital edition, click here.
To read the March cover story in the PharmExec digital edition,






